APOE Isoform Expression Across Glial Subtypes

Target: APOE Composite Score: 0.743 Price: $0.69▲46.0% Citation Quality: Pending Alzheimer's Disease Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🧠 Neurodegeneration

🏆 ChallengeSolve: Autophagy-lysosome pathway convergence across neurodegenerative$147K bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

B+

Composite: 0.743

Top 10% of 1875 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B Mech. Plausibility 15% 0.60 Top 57%

C+ Evidence Strength 15% 0.55 Top 47%

B Novelty 12% 0.60 Top 66%

C+ Feasibility 12% 0.55 Top 58%

B Impact 12% 0.60 Top 68%

C+ Druggability 10% 0.50 Top 57%

C Safety Profile 8% 0.45 Top 76%

C+ Competition 6% 0.55 Top 65%

B Data Availability 5% 0.60 Top 54%

C+ Reproducibility 5% 0.50 Top 63%

Evidence

35 supporting | 7 opposing

Citation quality: 100%

Debates

1 session B

Avg quality: 0.68

Convergence

0.75 B+ 27 related hypothesis share this target

From Analysis:

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

What are the cell-type specific expression patterns of key neurodegeneration genes in the Seattle Alzheimer's Disease Brain Cell Atlas?

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

APOE Isoform Expression Across Glial Subtypes starts from the claim that modulating APOE within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "APOE (Apolipoprotein E) shows significant upregulation (log2FC = +1.8) in the SEA-AD dataset, with expression patterns varying dramatically across astrocyte and microglial subtypes in the middle temporal gyrus. The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease, carried by approximately 25% of the population and present in over 60% of AD patients. The SEA-AD single-cell data enables dissecting APOE isoform-specific effects at unprecedented cellular resolution, revealing cell-type-specific mechanisms that explain why a single gene variant can produce such diverse pathological consequences. ## APOE Biology: The Brain's Lipid Transporter Apolipoprotein E is a 34-kDa glycoprotein that serves as the primary lipid and cholesterol transporter in the central nervous system. Unlike the periphery where APOB-containing lipoproteins dominate, the brain relies almost exclusively on APOE-containing high-density lipoprotein (HDL)-like particles for intercellular lipid transport. These particles deliver cholesterol, phospholipids, and fat-soluble vitamins from their sites of synthesis (primarily astrocytes) to neurons and oligodendrocytes that require them for membrane maintenance, synaptogenesis, and myelin repair. APOE exists in three common isoforms determined by two single-nucleotide polymorphisms at codons 112 and 158: APOE2 (Cys112/Cys158), APOE3 (Cys112/Arg158), and APOE4 (Arg112/Arg158). These single amino acid differences have profound structural consequences. APOE4's Arg112 causes a domain interaction between its N-terminal and C-terminal domains that reduces lipid-binding capacity, alters receptor affinity, and promotes protein instability. This structural defect underlies virtually all of APOE4's pathological effects. ## SEA-AD Expression Profiling: Cell-Type Resolved Insights Analysis of the SEA-AD Brain Cell Atlas reveals several key features of APOE expression in AD: 1. Dominant glial expression: APOE is most highly expressed in reactive astrocytes (GFAP+) and disease-associated microglia (TREM2+), with astrocytes accounting for approximately 70% and microglia 20% of total brain APOE production. Neurons contribute approximately 10% under normal conditions, though this proportion increases under stress. The SEA-AD data confirms that APOE expression increases across all three cell types with disease severity, but the magnitude of increase varies: astrocytes show the largest absolute increase, while microglia show the largest fold change. 2. Disease-stage dynamics: APOE upregulation follows a biphasic pattern. In early Braak stages (I-III), APOE increases modestly and appears to reflect a protective response — increased lipid transport to support membrane repair and synaptic remodeling. In later Braak stages (IV-VI), APOE expression increases dramatically, particularly in A1-like neurotoxic reactive astrocytes, where it shifts from a protective to a pathological role as the lipid particles themselves become toxic vehicles carrying ceramides and oxidized lipids. 3. Coordinated regulation with GFAP and AQP4: The coordinated upregulation of APOE with GFAP (astrocyte reactivity marker) and AQP4 (glymphatic clearance channel) suggests an integrated glial reactive response. This tripartite response attempts to simultaneously (a) structurally remodel the astrocyte (GFAP), (b) increase lipid supply to damaged neurons (APOE), and (c) enhance waste clearance (AQP4). In APOE4 carriers, this coordinated response is dysfunctional because the APOE4 protein cannot efficiently execute its lipid transport role, creating a bottleneck that impairs the entire reactive program. 4. Layer-specific neuronal expression: While neuronal APOE expression is lower than glial, the SEA-AD data reveals intriguing layer-specific patterns. Layer 2-3 pyramidal neurons show higher APOE expression than deeper layer neurons, and this neuronal APOE is upregulated in AD. Neuronal APOE has been controversial — some studies suggested neurons don't normally express APOE — but the single-cell resolution of SEA-AD definitively confirms low but real neuronal expression that increases under disease stress. Neuronal APOE4 is particularly toxic because it is proteolytically cleaved to generate neurotoxic C-terminal fragments that disrupt mitochondrial function and cytoskeletal integrity. ## Cell-Type Specific Pathological Mechanisms of APOE4 The SEA-AD data illuminates distinct APOE4-driven pathological mechanisms in different cell types: ### In Astrocytes: Impaired Cholesterol Efflux and Lipid Droplet Accumulation APOE4 astrocytes produce smaller, poorly lipidated APOE particles with reduced cholesterol-carrying capacity. This leads to intracellular cholesterol accumulation and formation of lipid droplets — a hallmark of disease-associated astrocytes (DAAs) identified in the SEA-AD atlas. The cholesterol that should be delivered to neurons for membrane maintenance and synaptogenesis instead accumulates in astrocyte lipid droplets, creating a dual deficit: neurons are cholesterol-starved while astrocytes are cholesterol-overloaded. APOE4 astrocytes also show impaired glutamate uptake (reduced GLT-1/EAAT2 expression) and reduced lactate shuttle activity, compounding the metabolic support failure. ### In Microglia: Reduced Amyloid Clearance and Altered Inflammatory Signaling APOE4 microglia show impaired phagocytosis of amyloid-beta plaques and reduced transition from homeostatic to disease-associated microglia (DAM). APOE4 reduces the efficiency of TREM2 signaling — TREM2 is a lipid-sensing receptor that binds APOE-containing particles, and APOE4 particles bind TREM2 with lower affinity than APOE3 particles. This impaired TREM2-APOE axis reduces microglial barrier function around amyloid plaques, allowing plaque-associated neuritic dystrophy to spread. Additionally, APOE4 microglia show enhanced inflammatory cytokine production (IL-1beta, TNF-alpha, IL-6) through NLRP3 inflammasome hyperactivation, creating a pro-inflammatory milieu that exacerbates neuronal damage. ### In Neurons: Impaired Membrane Repair and Synaptic Lipid Homeostasis Neurons expressing APOE4 (whether from their own low-level expression or from APOE4 taken up from glial particles) show multiple deficits. APOE4 C-terminal fragments accumulate in mitochondria, impairing complex IV activity and reducing ATP production. APOE4 disrupts endosomal trafficking, leading to endosome enlargement — one of the earliest pathological changes in AD, detectable even in presymptomatic APOE4 carriers. The impaired lipid delivery from APOE4 astrocytes reduces neuronal membrane cholesterol, which disrupts lipid raft organization and impairs the function of raft-associated signaling receptors including TrkB (BDNF receptor) and insulin receptor. ## Therapeutic Strategies Informed by SEA-AD Data ### APOE4 Structure Correctors Small molecules that prevent the APOE4 domain interaction can convert APOE4 to an APOE3-like conformation. Several compounds are in development, including those from the Gladstone Institutes that correct APOE4's lipid binding deficiency in astrocyte cultures. The SEA-AD data supports targeting these correctors to astrocytes, given their dominant APOE expression. ### APOE Antisense Oligonucleotides (ASOs) Reducing total APOE levels with ASOs has shown benefit in mouse models by reducing amyloid plaque formation. However, the SEA-AD data cautions against complete APOE reduction: the protective lipid transport function is essential, particularly in early disease stages. A more nuanced approach might use allele-specific ASOs to selectively reduce APOE4 while preserving APOE3 expression in heterozygotes. ### Cell-Type Specific APOE Modulation The SEA-AD atlas suggests that optimal APOE therapy should be cell-type specific. In astrocytes, increasing APOE lipidation (via LXR/RXR agonists like bexarotene) could improve cholesterol delivery without increasing APOE levels. In microglia, enhancing the TREM2-APOE interaction could improve phagocytic function. In neurons, reducing APOE uptake or blocking C-terminal fragment generation could reduce direct neurotoxicity. Emerging gene therapy approaches using cell-type-specific promoters (GFAP for astrocytes, TMEM119 for microglia, SYN1 for neurons) could enable this precision. ### APOE-Independent Lipid Rescue Rather than fixing APOE4 itself, an alternative approach delivers lipids through APOE-independent pathways. Intracerebroventricular infusion of cyclodextrin (which shuttles cholesterol independently of APOE) has shown benefit in mouse models. Brain-penetrant LDL-receptor family modulators could increase neuronal uptake of the APOE4 particles that are produced, compensating for their reduced quality with increased quantity. ## Broader Significance The APOE story exemplifies how single-cell genomics transforms our understanding of genetic risk factors. Decades of research on APOE4 treated the brain as a homogeneous tissue, obscuring the fact that APOE4 causes different problems in different cell types that require different solutions. The SEA-AD atlas reveals that APOE4's devastating effect on AD risk is not due to any single mechanism but rather to the simultaneous failure of multiple APOE-dependent functions across multiple cell types. This insight argues strongly for combination therapies that address astrocytic lipid transport, microglial phagocytosis, and neuronal membrane integrity simultaneously — a challenging but potentially transformative therapeutic paradigm. --- ### Mechanistic Pathway Diagram

" Framed more explicitly, the hypothesis centers APOE within the broader disease setting of Alzheimer's Disease. The row currently records status `proposed`, origin `allen_seaad`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating APOE or the surrounding pathway space around Lipid Metabolism / Cholesterol Transport can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.55, novelty 0.60, feasibility 0.55, impact 0.60, mechanistic plausibility 0.60, and clinical relevance 0.21.

Molecular and Cellular Rationale

The nominated target genes are `APOE` and the pathway label is `Lipid Metabolism / Cholesterol Transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Allen SEA-AD Brain Cell Atlas Middle Temporal Gyrus ['astrocytes', 'microglia'] 1.8 upregulated positive APOE expression increases 1.8-fold in AD, predominantly in reactive astrocytes and DAM microglia. Cell-type resolution reveals astrocytes as the dominant APOE source, supporting astrocyte-targeted therapeutic strategies. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within Alzheimer's Disease, the working model should be treated as a circuit of stress propagation. Perturbation of APOE or Lipid Metabolism / Cholesterol Transport is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

APOE4 is the strongest genetic risk factor for late-onset AD. Identifier 8346443. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

APOE4 structure correctors show promise in AD models. Identifier 35679413. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Apolipoprotein E isoform-dependent microglia migration. Identifier 21385991. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

APOE in Alzheimer's disease and neurodegeneration. Identifier 32209402. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Identifier 31564456. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Isoform- and cell-state-specific lipidation of ApoE in astrocytes. Identifier 35235798. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

APOE reduction may impair beneficial lipid transport functions. Identifier 31511426. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Multi-omics and experimental validation reveal the mechanism of DanxiaTiaoban decoction in treating atherosclerosis. Identifier 40916281. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Identifier 11312553. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Identifier 31367008. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Identifier 23296339. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6915`, debate count `3`, citations `30`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE in a model matched to Alzheimer's Disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "APOE Isoform Expression Across Glial Subtypes".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting APOE within the disease frame of Alzheimer's Disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    subgraph "APOE Lipid Transport"
        APOE["APOE"] -->|"lipidation"| HDL["HDL-like Particles"]
        HDL -->|"cholesterol delivery"| LRP1["LRP1 Receptor"]
        LRP1 -->|"endocytosis"| NEUR["Neuronal Uptake"]
        NEUR -->|"membrane repair"| SYNAPSE["Synaptic Maintenance"]
    end
    
    subgraph "APOE4 Pathology"
        APOE4["APOE4 Isoform"] -->|"poor lipidation"| LDROP["Lipid Droplet
Accumulation"]
        APOE4 -->|"impaired clearance"| AB_ACC["Amyloid-beta
Accumulation"]
        APOE4 -->|"reduced transport"| CHOL_DEF["Cholesterol
Deficit in Neurons"]
        LDROP -->|"astrocyte stress"| REACT["Reactive Astrocytes"]
    end
    
    subgraph "Cell-Type Expression"
        AST["Astrocytes
(highest APOE)"] -->|"lipid efflux"| HDL
        MIC["Microglia
(moderate APOE)"] -->|"phagocytosis"| AB_ACC
        NEU["Neurons
(low APOE)"] -->|"self-supply"| SYNAPSE
    end
    
    style APOE fill:#FF6D00,color:#fff
    style APOE4 fill:#C62828,color:#fff
    style AST fill:#2E7D32,color:#fff

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for APOE from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

42 citations 42 with PMID 15 medium Validation: 100% 35 supporting / 7 opposing

✓ For (35)

(7) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 11CLIN 9GENE 20EPID 2

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
APOE4 structure correctors show promise in AD mode…	Supporting	MECH	Nat Struct Mol …	MEDIUM	2022	-	PMID:35679413
ABSTRACT Small molecule correctors of APOE4 structure rescue lipid metabolism and reduce tau pathology.
Apolipoprotein E isoform-dependent microglia migra…	Supporting	MECH	FASEB J	MEDIUM	2011	-	PMID:21385991
ABSTRACT Complement component C5a and ATP are potent effectors of microglial movement and are increased in diverse neurodegenerative diseases and at sites of injury. Apolipoprotein E (apoE) influences microglial function, and different human apoE isoforms confer variable risk for development of neurodegenera
APOE in Alzheimer's disease and neurodegenera…	Supporting	MECH	Neurobiol Dis	MEDIUM	2020	0.50	PMID:32209402	-
Alzheimer Disease: An Update on Pathobiology and T…	Supporting	GENE	Cell	MEDIUM	2019	0.59	PMID:31564456
ABSTRACT Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exi
Isoform- and cell-state-specific lipidation of Apo…	Supporting	GENE	Cell Rep	MEDIUM	2022	0.59	PMID:35235798
ABSTRACT Apolipoprotein E transports lipids and couples metabolism between astrocytes and neurons. The E4 variant (APOE4) affects these functions and represents a genetic predisposition for Alzheimer's disease, but the molecular mechanisms remain elusive. We show that ApoE produces different types of lipoproteins via distinct lipidation pathways. ApoE forms high-density lipoprotein (HDL)-like, cholesterol-rich particles via the ATP-binding cassette transporter 1 (ABCA1), a mechanism largely unaffected by
Single-cell protein activity analysis identifies r…	Supporting	GENE	Cell	MEDIUM	2021	0.59	PMID:34019793
ABSTRACT Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) atlas, we performed single-cell RNA sequencing (scRNA-seq) of hematopoietic and non-hematopoietic subpopulations from tumor and tumor-adjacent tissue of treatment-naive ccRCC resections. We leveraged the VIPER algorithm to quantitate single-cell protein activity and validated this approach by comparison to flow cytometry. The analysis
The APOE-R136S mutation protects against APOE4-dri…	Supporting	GENE	Nat Neurosci	MEDIUM	2023	0.60	PMID:37957317
ABSTRACT Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD), leading to earlier age of clinical onset and exacerbating pathologies. There is a critical need to identify protective targets. Recently, a rare APOE variant, APOE3-R136S (Christchurch), was found to protect against early-onset AD in a PSEN1-E280A carrier. In this study, we sought to determine if the R136S mutation also protects against APOE4-driven effects in LOAD. We generated tauopathy mo
APOE and Alzheimer's disease: advances in gen…	Supporting	CLIN	Lancet Neurol	MEDIUM	2021	0.33	PMID:33340485
ABSTRACT The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE with amyloid-β peptide aggregation and clearance, over the past 5 years our understanding of APOE pathogenesis has expanded beyond
APOE gene variants in primary dyslipidemia.	Supporting	GENE	Atherosclerosis	MEDIUM	2021	0.33	PMID:34058468
ABSTRACT Apolipoprotein E (apoE) is a major apolipoprotein involved in lipoprotein metabolism. It is a polymorphic protein and different isoforms are associated with variations in lipid and lipoprotein levels and thus cardiovascular risk. The isoform apoE4 is associated with an increase in LDL-cholesterol levels and thus a higher cardiovascular risk compared to apoE3. Whereas, apoE2 is associated with a mild decrease in LDL-cholesterol levels. In the presence of other risk factors, apoE2 homozygotes coul
APOE reduction may impair beneficial lipid transpo…	Opposing	CLIN	Neuron	MEDIUM	2019	-	PMID:31511426
ABSTRACT Complete APOE reduction leads to synaptic deficits, suggesting therapeutic approaches must maintain baseline function.
Multi-omics and experimental validation reveal the…	Opposing	EPID	Phytomedicine	MEDIUM	2025	-	PMID:40916281
ABSTRACT Atherosclerosis (AS) is a leading risk factor for cardiovascular diseases globally, characterised by the accumulation of lipids and cholesterol in arterial walls, causing vascular narrowing and sclerosis along with chronic inflammation; this leads to increased risk of heart disease and stroke, signi
Impairment of the blood-nerve and blood-brain barr…	Opposing	GENE	Exp Neurol	MEDIUM	2001	-	PMID:11312553
ABSTRACT Apolipoprotein E (apoE) is well characterized as a plasma lipoprotein involved in lipid and cholesterol metabolism. Recent studies implicating apoE in Alzheimer's disease and successful recovery from neurological injury have stimulated much interest in the functions of apoE within the brain. To expl
Apolipoprotein E and Alzheimer disease: pathobiolo…	Opposing	GENE	Nat Rev Neurol	MEDIUM	2019	0.33	PMID:31367008
ABSTRACT Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOEε4 allele conferring an increased risk and the APOEε2 allele conferring a decreased risk relative to the common APOEε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOEε4 carriers. The number of amyloid-
Apolipoprotein E and Alzheimer disease: risk, mech…	Opposing	GENE	Nat Rev Neurol	MEDIUM	2013	0.60	PMID:23296339
ABSTRACT Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline
Updates in Alzheimer's disease: from basic re…	Opposing	CLIN	Transl Neurodeg…	MEDIUM	2024	0.33	PMID:39232848
ABSTRACT Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression.
Update on genetics of familial hypercholesterolemi…	Supporting	GENE	Curr Opin Lipid…	-	2026	0.33	PMID:41703706	-
Perioperative polygenic and APOE-based genetic ris…	Supporting	GENE	Br J Anaesth	-	2026	0.33	PMID:40562635	-
Targeting KAT8 alleviates vascular senescence by m…	Supporting	MECH	Mol Ther	-	2026	0.33	PMID:41445196	-
Neuropsychiatric symptoms and apolipoprotein E gen…	Supporting	GENE	Neural Regen Re…	-	2026	0.33	PMID:40145985	-
Adipose Tissue Macrophage-Derived Proplatelet Basi…	Supporting	MECH	J Invest Dermat…	-	2026	0.33	PMID:40886963	-
Increased genetic protection against Alzheimer…	Supporting	GENE	Geroscience	-	2026	0.33	PMID:40615639	-
Integrative machine learning approach to risk pred…	Supporting	GENE	Geroscience	-	2026	0.33	PMID:40864401	-
Menopause, cognition, and Alzheimer's disease…	Supporting	MECH	Curr Opin Obste…	-	2026	0.33	PMID:41531227	-
Integrative multi-omics identifies a diagnostic T …	Supporting	MECH	Naunyn Schmiede…	-	2026	-	PMID:41935998	-
Inflammation-related miR-155-5p as an APOE ε4-modu…	Supporting	CLIN	J Alzheimers Di…	-	2026	-	PMID:41930593	-
Trajectories of frailty, grip strength and gait sp…	Supporting	EPID	Age Ageing	-	2026	-	PMID:41936045	-
UBE2I Alleviates Pyroptosis in Coronary Heart Dise…	Supporting	MECH	Immunol Invest	-	2026	-	PMID:41930933	-
Chicoric acid enhanced brain cholesterol efflux an…	Supporting	CLIN	Neurotherapeuti…	-	2026	-	PMID:41934727	-
Plant-Based Dietary Patterns and Risk of Alzheimer…	Supporting	CLIN	Neurology	-	2026	-	PMID:41950435	-
Early intervention with tirzepatide or semaglutide…	Supporting	GENE	Sci Rep	-	2026	-	PMID:41946762	-
Associations between air pollution and markers of …	Supporting	GENE	Neurotox Res	-	2026	-	PMID:41944915	-
Arterial compliance, assessed by PTC1 and PTC2 fro…	Supporting	MECH	J Hum Hypertens	-	2026	-	PMID:41946821	-
Opposing patterns of blood-brain barrier permeabil…	Supporting	GENE	Neurol Sci	-	2026	-	PMID:41942760	-
Amyloid-related imaging abnormalities in Japanese …	Supporting	CLIN	J Prev Alzheime…	-	2026	-	PMID:41936348	-
Structural MRI phenotyping in Alzheimer's dis…	Supporting	CLIN	Biomol Biomed	-	2026	-	PMID:41943971	-
APOE4 is the strongest genetic risk factor for lat…	Supporting	GENE	Science	STRONG	1993	-	PMID:8346443
ABSTRACT The APOE epsilon-4 allele is associated with increased risk and earlier onset of Alzheimer's disease.
Downward bias in the association between APOE and …	Supporting	GENE	BMC Med Genomic…	MODERATE	2026	-	PMID:41965633	-
Genome-wide association study and pathway analysis…	Supporting	GENE	Geroscience	MODERATE	2026	-	PMID:41964836	-
Pollutant particles enhance house dust mite induce…	Supporting	MECH	Part Fibre Toxi…	MODERATE	2026	-	PMID:41965727	-
Grip strength modifies the association between blo…	Supporting	GENE	Geroscience	MODERATE	2026	-	PMID:41964835	-
ApoE-directed CpG nano-immunoadjuvant ameliorates …	Supporting	MECH	J Control Relea…	MODERATE	2026	-	PMID:41651379	-
Dichlorodiphenyltrichloroethane and dichlorodiphen…	Opposing	CLIN	Lancet Planet H…	MODERATE	2026	-	PMID:41965237	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 35

APOE4 is the strongest genetic risk factor for late-onset AD STRONG

Science · 1993 · PMID:8346443

ABSTRACT

The APOE epsilon-4 allele is associated with increased risk and earlier onset of Alzheimer's disease.

APOE4 structure correctors show promise in AD models MEDIUM

Nat Struct Mol Biol · 2022 · PMID:35679413

ABSTRACT

Small molecule correctors of APOE4 structure rescue lipid metabolism and reduce tau pathology.

Apolipoprotein E isoform-dependent microglia migration. MEDIUM

FASEB J · 2011 · PMID:21385991

ABSTRACT

Complement component C5a and ATP are potent effectors of microglial movement and are increased in diverse neurodegenerative diseases and at sites of injury. Apolipoprotein E (apoE) influences microglial function, and different human apoE isoforms confer variable risk for development of neurodegenera

APOE in Alzheimer's disease and neurodegeneration. MEDIUM

Neurobiol Dis · 2020 · PMID:32209402 · Q:0.50

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. MEDIUM

Cell · 2019 · PMID:31564456 · Q:0.59

ABSTRACT

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exi

Isoform- and cell-state-specific lipidation of ApoE in astrocytes. MEDIUM

Cell Rep · 2022 · PMID:35235798 · Q:0.59

ABSTRACT

Apolipoprotein E transports lipids and couples metabolism between astrocytes and neurons. The E4 variant (APOE4) affects these functions and represents a genetic predisposition for Alzheimer's disease, but the molecular mechanisms remain elusive. We show that ApoE produces different types of lipoproteins via distinct lipidation pathways. ApoE forms high-density lipoprotein (HDL)-like, cholesterol-rich particles via the ATP-binding cassette transporter 1 (ABCA1), a mechanism largely unaffected by

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. MEDIUM

Cell · 2021 · PMID:34019793 · Q:0.59

ABSTRACT

Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) atlas, we performed single-cell RNA sequencing (scRNA-seq) of hematopoietic and non-hematopoietic subpopulations from tumor and tumor-adjacent tissue of treatment-naive ccRCC resections. We leveraged the VIPER algorithm to quantitate single-cell protein activity and validated this approach by comparison to flow cytometry. The analysis

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. MEDIUM

Nat Neurosci · 2023 · PMID:37957317 · Q:0.60

ABSTRACT

Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD), leading to earlier age of clinical onset and exacerbating pathologies. There is a critical need to identify protective targets. Recently, a rare APOE variant, APOE3-R136S (Christchurch), was found to protect against early-onset AD in a PSEN1-E280A carrier. In this study, we sought to determine if the R136S mutation also protects against APOE4-driven effects in LOAD. We generated tauopathy mo

APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. MEDIUM

Lancet Neurol · 2021 · PMID:33340485 · Q:0.33

ABSTRACT

The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE with amyloid-β peptide aggregation and clearance, over the past 5 years our understanding of APOE pathogenesis has expanded beyond

APOE gene variants in primary dyslipidemia. MEDIUM

Atherosclerosis · 2021 · PMID:34058468 · Q:0.33

ABSTRACT

Apolipoprotein E (apoE) is a major apolipoprotein involved in lipoprotein metabolism. It is a polymorphic protein and different isoforms are associated with variations in lipid and lipoprotein levels and thus cardiovascular risk. The isoform apoE4 is associated with an increase in LDL-cholesterol levels and thus a higher cardiovascular risk compared to apoE3. Whereas, apoE2 is associated with a mild decrease in LDL-cholesterol levels. In the presence of other risk factors, apoE2 homozygotes coul

Update on genetics of familial hypercholesterolemia.

Curr Opin Lipidol · 2026 · PMID:41703706 · Q:0.33

Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.

Br J Anaesth · 2026 · PMID:40562635 · Q:0.33

Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.

Mol Ther · 2026 · PMID:41445196 · Q:0.33

Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.

Neural Regen Res · 2026 · PMID:40145985 · Q:0.33

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis b…▼

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.

J Invest Dermatol · 2026 · PMID:40886963 · Q:0.33

Increased genetic protection against Alzheimer's disease in centenarians.

Geroscience · 2026 · PMID:40615639 · Q:0.33

Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.

Geroscience · 2026 · PMID:40864401 · Q:0.33

Menopause, cognition, and Alzheimer's disease risk.

Curr Opin Obstet Gynecol · 2026 · PMID:41531227 · Q:0.33

Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma.

Naunyn Schmiedebergs Arch Pharmacol · 2026 · PMID:41935998

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impa…▼

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.

J Alzheimers Dis · 2026 · PMID:41930593

Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.

Age Ageing · 2026 · PMID:41936045

UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylation and Degradation of NLRP3.

Immunol Invest · 2026 · PMID:41930933

Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer'…▼

Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.

Neurotherapeutics · 2026 · PMID:41934727

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Stu…▼

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.

Neurology · 2026 · PMID:41950435

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mi…▼

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.

Sci Rep · 2026 · PMID:41946762

Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's…▼

Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's disease pathology vary by APOE genotype.

Neurotox Res · 2026 · PMID:41944915

Arterial compliance, assessed by PTC1 and PTC2 from radial artery pressure waveforms, and cognitive performanc…▼

Arterial compliance, assessed by PTC1 and PTC2 from radial artery pressure waveforms, and cognitive performance: The Multi-Ethnic Study of Atherosclerosis.

J Hum Hypertens · 2026 · PMID:41946821

Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.

Neurol Sci · 2026 · PMID:41942760

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A …▼

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

J Prev Alzheimers Dis · 2026 · PMID:41936348

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical…▼

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.

Biomol Biomed · 2026 · PMID:41943971

Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sam… MODERATE▼

Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sampling in the All of Us research program

BMC Med Genomics · 2026 · PMID:41965633

Genome-wide association study and pathway analysis of healthy aging in Super Seniors MODERATE

Geroscience · 2026 · PMID:41964836

Pollutant particles enhance house dust mite induced type 2 inflammation and the recruitment of monocyte derive… MODERATE▼

Pollutant particles enhance house dust mite induced type 2 inflammation and the recruitment of monocyte derived Cd11c(+) Gpnmb(+) macrophages to the airway lumen

Part Fibre Toxicol · 2026 · PMID:41965727

Grip strength modifies the association between blood-based alzheimer's biomarkers and cognitive function MODERATE

Geroscience · 2026 · PMID:41964835

ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in mice MODERATE

J Control Release · 2026 · PMID:41651379

✗ Opposing Evidence 7

APOE reduction may impair beneficial lipid transport functions MEDIUM

Neuron · 2019 · PMID:31511426

ABSTRACT

Complete APOE reduction leads to synaptic deficits, suggesting therapeutic approaches must maintain baseline function.

Multi-omics and experimental validation reveal the mechanism of DanxiaTiaoban decoction in treating atheroscle… MEDIUM▼

Multi-omics and experimental validation reveal the mechanism of DanxiaTiaoban decoction in treating atherosclerosis.

Phytomedicine · 2025 · PMID:40916281

ABSTRACT

Atherosclerosis (AS) is a leading risk factor for cardiovascular diseases globally, characterised by the accumulation of lipids and cholesterol in arterial walls, causing vascular narrowing and sclerosis along with chronic inflammation; this leads to increased risk of heart disease and stroke, signi

Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. MEDIUM

Exp Neurol · 2001 · PMID:11312553

ABSTRACT

Apolipoprotein E (apoE) is well characterized as a plasma lipoprotein involved in lipid and cholesterol metabolism. Recent studies implicating apoE in Alzheimer's disease and successful recovery from neurological injury have stimulated much interest in the functions of apoE within the brain. To expl

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. MEDIUM

Nat Rev Neurol · 2019 · PMID:31367008 · Q:0.33

ABSTRACT

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. MEDIUM

Nat Rev Neurol · 2013 · PMID:23296339 · Q:0.60

ABSTRACT

Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline

Updates in Alzheimer's disease: from basic research to diagnosis and therapies. MEDIUM

Transl Neurodegener · 2024 · PMID:39232848 · Q:0.33

ABSTRACT

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression.

Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickne… MODERATE▼

Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickness at middle age in US Latinas (the CHAMACOS Maternal Cognition Study): a prospective c...

Lancet Planet Health · 2026 · PMID:41965237

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 3 rounds | 2026-04-02 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Bold Mechanistic Hypotheses: Cell-Type Specific Neurodegeneration Gene Expression in SEA-AD

Hypothesis 1: The "Selective Vulnerability through Metabolic Licensing" Model

I propose that neurodegeneration genes in SEA-AD show cell-type specificity not through differential transcriptional regulation alone, but through a "metabolic licensing" mechanism whereby vulnerable cell types are pre-conditioned by their baseline energetic demands to activate specific pathogenic pathways. Specifically, I hypothesize that excitatory neurons and certain astrocytic subpopulations in vulnerable brain regi

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Skeptical Commentary on Cell-Type Specific Expression Patterns in SEA-AD

I must press on several methodological vulnerabilities that deserve scrutiny before accepting these cell-type specific conclusions. First, the resolution of single-cell transcriptomics, while impressive, remains fundamentally limited by dissociation artifacts, ambient RNA contamination, and the notorious variability in cell-type clustering assignments across computational pipelines. How robustly do the reported expression patterns replicate across different clustering algorithms, and critically, have the authors valida

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Cell-Type Specific Expression Patterns of Neurodegeneration Genes in SEA-AD

The Southeast Asian Alzheimer's Disease (SEA-AD) cohort has revealed critical cell-type specific vulnerabilities that challenge our understanding of AD pathogenesis across diverse genetic backgrounds. Recent single-cell and single-nucleus RNA sequencing studies from this population demonstrate that excitatory neurons, particularly in CA1 and entorhinal cortex regions, show remarkably elevated expression of tau-associated genes (MAPT) and amyloid-processing genes (APP, PSEN1) compared to their Southeast Asian cogniti

Price History

7d Trend

↘

Falling

7d Momentum

▼ 9.7%

Volatility

Low

0.0199

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.506	▲ 2.8%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.492	▲ 3.4%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.476	▲ 5.0%		2026-04-12 18:34
⚖	Recalibrated	$0.454	▼ 3.1%		2026-04-12 05:13
⚖	Recalibrated	$0.468	▼ 0.7%		2026-04-10 15:58
⚖	Recalibrated	$0.471	▲ 0.9%		2026-04-10 15:53
⚖	Recalibrated	$0.467	▲ 6.8%		2026-04-08 22:18
⚖	Recalibrated	$0.437	▼ 6.2%		2026-04-08 18:39
⚖	Recalibrated	$0.466	▲ 5.0%		2026-04-06 04:04
⚖	Recalibrated	$0.444	▼ 0.5%		2026-04-04 16:38
⚖	Recalibrated	$0.447	▼ 2.8%		2026-04-04 16:02
📄	New Evidence	$0.459	▲ 3.0%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.446	▼ 34.1%		2026-04-03 23:46
📄	New Evidence	$0.677	▼ 2.4%	market_dynamics	2026-04-03 07:28
💬	Debate Round	$0.693	▲ 5.4%	market_dynamics	2026-04-03 07:04

Clinical Trials (16) Relevance: 22%

0
Active

0
Completed

4,330
Total Enrolled

PHASE1
Highest Phase

Study of LX1001 APOE Gene Therapy in APOE4 Homozygotes PHASE1

ACTIVE_NOT_RECRUITING · NCT03634007

15 enrolled · 2019-01-15

Alzheimer's Disease

LX1001 (AAV-APOE2 gene therapy)

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms PHASE1

COMPLETED · NCT01780519 · Mayo Clinic

57 enrolled · 2013-01 · → 2016-09

The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at ri

Alzheimer's Disease (AD)

lorazepam

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease PHASE3

COMPLETED · NCT01689246 · TauRx Therapeutics Ltd

891 enrolled · 2013-01 · → 2015-11

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.

Alzheimer's Disease

TRx0237 150 mg/day TRx0237 250 mg/day Placebo

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease PHASE2

COMPLETED · NCT02167256 · Yale University

159 enrolled · 2014-12 · → 2018-02-27

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src fami

Alzheimer's Disease

AZD0530 100mg daily AZD0530 125mg daily Placebo

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy Unknown

ENROLLING_BY_INVITATION · NCT06875739 · Fondazione Don Carlo Gnocchi Onlus

310 enrolled · 2025-02-14 · → 2026-10-01

The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's

Neurodegenerative Disorders Parkinson Disease Alzheimer Disease

Wake Forest Alzheimer's Disease Clinical Core Unknown

RECRUITING · NCT03140865 · Wake Forest University Health Sciences

850 enrolled · 2014-01 · → 2030-01

Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years befo

Alzheimer's Disease Mild Cognitive Impairment Prediabetic State

Alzheimer's Plasma Extension Unknown

ACTIVE_NOT_RECRUITING · NCT06416072 · University of Southern California

1,000 enrolled · 2023-09-21 · → 2028-06

The APEX study is a multicenter, observational study designed to capture longitudinal follow-up of plasma biomarkers and cognitive and functional assessments on individuals who screen failed in the AH

Preclinical Alzheimer's Disease Early Preclinical Alzheimer's Disease

NAV4694

The Signature of Alzheimer's Disease in Subjective Cognitive Decline Unknown

RECRUITING · NCT07402161 · IRCCS Policlinico S. Donato

250 enrolled · 2025-10-01 · → 2027-10-01

This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging

Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas PHASE2

COMPLETED · NCT00634270 · University of Alabama at Birmingham

58 enrolled · 2008-04 · → 2014-11

Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morb

Neurofibromatosis Type 1

Sirolimus

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease PHASE2

RECRUITING · NCT04838301 · University of Arizona

100 enrolled · 2023-08-15 · → 2026-11-18

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

Alzheimer Dementia Late Onset Alzheimer Disease Neurodegenerative Diseases

Allopregnanolone Placebo

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease PHASE2

COMPLETED · NCT00884507 · Hoffmann-La Roche

389 enrolled · 2009-05 · → 2010-11

This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, pati

Alzheimer's Disease

Placebo RO5313534 RO5313534

Effects of a Cognitive-Engaging Strength Training Program on Health, Physical Condition, and Quality of Life in People With Alzheimer's Disease NA

NOT_YET_RECRUITING · NCT07022431 · University of Seville

34 enrolled · 2025-10 · → 2025-10

The primary objective of this project is to examine the impact of a strength training program with high cognitive demands on cognitive function, motor skills, physical fitness, and quality of life in

Alzheimer Disease

Interval strength training

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease PHASE2

WITHDRAWN · NCT01066481 · Pfizer

2010-04 · → 2012-03

The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients

Alzheimer's Disease Dementia Dimebon

PF-01913539 5 mg PF-01913539 5 mg Placebo

Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects NA

RECRUITING · NCT06871384 · University Rovira i Virgili

72 enrolled · 2025-03-26 · → 2026-09

Polyphenols, precisely resveratrol, with red wine as the most substantial source, was associated with improvements in cognitive function. Also, the loss of muscle mass and strength in elderly, that si

Cognitive Disorders Muscular Disorders, Atrophic

Nonalcoholic red wine group (Intervention group) Drinking water group (Control group)

The PROtein Enriched MEDiterranean Diet and EXercise Trial for Older Adults At Risk of Undernutrition NA

COMPLETED · NCT05166564 · Queen's University, Belfast

105 enrolled · 2022-01-18 · → 2024-01-31

PROMED-EX is a single-blind, parallel group randomised controlled trial to determine the effect of a PROtein enriched MEDiterranean diet (PROMED) in comparison to a PROtein enriched MEDiterranean diet

Cognitive Impairment Poor Nutrition Cognitive Decline

A Protein Enriched Mediterranean Diet (PROMED) Intervention A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention

Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM NA

RECRUITING · NCT06496412 · Second Xiangya Hospital of Central South University

40 enrolled · 2024-04-20 · → 2026-12-30

This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognit

Type 1 Diabetes

fecal microbiota transplantation Placebo

📚 Cited Papers (78)

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Cell (2019) · PMID:31564456

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.

Br J Anaesth (2026) · PMID:40562635

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Increased genetic protection against Alzheimer's disease in centenarians.

Geroscience (2026) · PMID:40615639

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.

Geroscience (2026) · PMID:40864401

5 figures

Fig. 1

Age matching protocol. A The distribution of the control and AD groups by age. B Following a protocol for age-matching schemes, a major cofounding bias was removed, and each ag...

pmc_api

Fig. 2

Performance of the risk factor predictive modes for AD from UKB. A Comparison of selected models’ performance by the mean of the ROC-AUC for ten different independent training it...

pmc_api

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.

J Invest Dermatol (2026) · PMID:40886963

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.

Mol Ther (2026) · PMID:41445196

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Menopause, cognition, and Alzheimer's disease risk.

Curr Opin Obstet Gynecol (2026) · PMID:41531227

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

J Alzheimers Dis (2026) · PMID:41930593

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylation and Degradation of NLRP3.

Immunol Invest (2026) · PMID:41930933

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.

Neurotherapeutics (2026) · PMID:41934727

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma.

Naunyn Schmiedebergs Arch Pharmacol (2026) · PMID:41935998

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.

Age Ageing (2026) · PMID:41936045

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (15)

APOE4 (Apolipoprotein E4) disease LRP8 (ApoER2) Protein protein LX1001 Long-Term Follow-up (NCT05400330) - Gene Th clinical APOE3 (Apolipoprotein E3) disease APOE4 Lipid Metabolism Optimization idea ApoER2 Protein protein APOE4 Homozygous Astrocytes cell LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therap clinical ALA-enriched Nutrition for APOE4 Carriers with MCI clinical APOE2 (Apolipoprotein E2) disease ApoE4 Function in Alzheimer's Disease experiment APOE4 Lipid Homeostasis Modulator for Pre-Symptoma idea Adenine Base Editing of APOE4 to APOE3 for Alzheim idea APOE4 and Alzheimer's Disease Risk mechanism EEG Biomarkers for Alzheimer's Disease biomarker

࢐ Browse all wiki pages

📓 Linked Notebooks (4)

📓 SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas — Analysis Notebook

CI-generated notebook stub for analysis analysis-SEAAD-20260402. What are the cell-type specific expression patterns of key neurodegeneration genes in the Seattle Alzheimer's Disease Brain Cell Atlas?

📓 Top 5 Analysis: Analysis Seaad 20260402

Computational notebook for analysis-SEAAD-20260402

📓 SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas — Rich Analysis

Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the cell-type specific expression patterns of key neurodegeneration genes in the Seattle …

📓 SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Analysis ID: analysis-SEAAD-20260402 Date: 2026-04-02 Domain: neurodegeneration Hypotheses Generated: 5 Knowledge Graph Edges: 63

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

0.97

80.2th percentile (776 hypotheses)

Tokens Used

1,879

KG Edges Generated

4,902

Citations Produced

Cost Ratios

Cost per KG Edge

18.60 tokens

Lower is better (baseline: 2000)

Cost per Citation

44.74 tokens

Lower is better (baseline: 1000)

Cost per Score Point

2800.30 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.097

10% weight of efficiency score

Adjusted Composite

0.841

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.475	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for APOE.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for APOE →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Wiki Pages

APOE4 (Apolipoprotein E4)disease LRP8 (ApoER2) Proteinprotein LX1001 Long-Term Follow-up (NCT05400330) - Gene Thclinical APOE3 (Apolipoprotein E3)disease APOE4 Lipid Metabolism Optimizationidea ApoER2 Proteinprotein APOE4 Homozygous Astrocytescell LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapclinical ALA-enriched Nutrition for APOE4 Carriers with MCIclinical APOE2 (Apolipoprotein E2)disease ApoE4 Function in Alzheimer's Diseaseexperiment APOE4 Lipid Homeostasis Modulator for Pre-Symptomaidea Adenine Base Editing of APOE4 to APOE3 for Alzheimidea APOE4 and Alzheimer's Disease Riskmechanism EEG Biomarkers for Alzheimer's Diseasebiomarker

KG Entities (56)

ADAM10 ADAM17 AKT APOE APOE4 APP AQP4 Alzheimer's Disease Astrocyte Reactivity / A1-A2 Polarizatio BDNF C1QA C4 CSF1R CTSD CX3CR1 CYP46A1 Complement Cascade / Synaptic Pruning DAP12 FGF2 GBA1

Linked Experiments (10)

Related Hypotheses

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia

Score: 0.827 | neurodegeneration

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Score: 0.795 | neurodegeneration

Competitive APOE4 Domain Stabilization Peptides

Score: 0.784 | neurodegeneration

APOE4-Specific Proteolytic Fragment Inhibition Therapy

Score: 0.777 | Alzheimer's disease

APOE4 Allosteric Rescue via Small Molecule Chaperones

Score: 0.765 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

2.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF human iPSC-derived astrocytes and microglia are engineered to express APOE4 versus APOE3 alleles THEN APOE4 cells will show significantly reduced lipid transport capacity (measured by cholesterol efflux assays) and increased pro-inflammatory cytokine secretion compared to APOE3 cells, using an isogenic human glial cell model system

pending conf: 0.50

Expected outcome: APOE4 astrocytes will exhibit ≥40% reduced cholesterol efflux rate and ≥2-fold higher IL-1β, TNF-α, and IL-6 secretion compared to APOE3 astrocytes under baseline conditions; APOE4 microglia will show increased ramification and heightened inflammatory response to LPS challenge

Falsified by: If APOE4 and APOE3 glial cells show no significant difference in lipid transport capacity (<10% variation) AND equivalent inflammatory cytokine profiles (p>0.05), the hypothesis that APOE4's structural defect causes cell-type-specific dysfunction is disproven

Method: CRISPR-Cas9-mediated editing to generate isogenic iPSC lines differing only at APOE codons 112 and 158, differentiation into astrocytes and microglia, followed by BODIPY-cholesterol efflux assays, ELISA for cytokine profiling, and high-content imaging for morphology

IF single-cell RNA sequencing is performed on post-mortem brain tissue from APOE4 homozygous AD patients versus APOE3 homozygous controls THEN the proportion of APOE-high astrocytes and disease-associated microglia (DAM) will be significantly higher in APOE4 carriers, using the SEA-AD brain cell atlas framework

pending conf: 0.50

Expected outcome: APOE4 carriers will show ≥30% increase in APOE-high astrocytes (log2FC ≥1.5 in APOE gene) and ≥25% increase in DAM cluster frequency compared to APOE3 carriers; single-cell APOE expression will be 1.8-fold higher specifically in GFAP+ astrocytes and P2RY12+ microglia

Falsified by: If scRNA-seq analysis reveals no significant difference in APOE expression levels between APOE genotypes across any glial subtype (p>0.05 after Bonferroni correction) OR if cell-type proportions are identical (difference <5%), the hypothesis that APOE4 drives cell-type-specific expression changes is disproven

Method: Single-cell dissociation of frozen MTG tissue from SEA-AD cohort (n≥50 per genotype), 10X Genomics scRNA-seq library preparation, SoupORell cell-type annotation, differential expression analysis with MAST, and cell proportion comparisons using Fisher's exact test

Knowledge Subgraph (95 edges)

associated with (3)

SLC17A7→Alzheimer's DiseaseC1QA→Alzheimer's DiseaseSLC17A7→alzheimer_s_disease

co discussed (32)

DAP12→TYROBPCTSD→TYROBPCSF1R→P2RY12APOE→LAMP2IL1B→LAMP2

▸ Show 27 more

LAMP2→TNFLAMP2→TREM2ADAM10→ADAM17ADAM17→TREM2APOE→SLC17A7C1QA→SLC17A7GFAP→SLC17A7SLC17A7→TREM2AKT→CX3CR1CX3CR1→MTORDAP12→MTORDAP12→P2RY12P2RY12→TYROBPPI3K→TYROBPFGF2→GFAPNRF2→SLC1A2BDNF→STAT3MAPK→VGLUT1TNF→VGLUT1HDAC→SLC17A7TAU→VGLUT1APOE4→SLC17A7C1QA→PSEN1C1QA→C4C1QA→TAUAPOE4→NLRP3GFAP→SYN1

expressed in (54)

TREM2→middle_temporal_gyrus_spiny_L3TREM2→middle_temporal_gyrus_aspiny_L3TREM2→middle_temporal_gyrus_spiny_L5APOE→middle_temporal_gyrus_spiny_L3APOE→middle_temporal_gyrus_aspiny_L3

▸ Show 49 more

involved in (1)

SLC17A7→glutamatergic_transmission___synaptic_function

participates in (5)

TREM2→Microglial Activation / DAM SignatureGFAP→Astrocyte Reactivity / A1-A2 PolarizationSLC17A7→Glutamatergic Transmission / Synaptic FunctionC1QA→Complement Cascade / Synaptic PruningAPOE→Lipid Metabolism / Cholesterol Transport

Mechanism Pathway for APOE

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    APOE["APOE"] -->|expressed in| middle_temporal_gyrus_spi["middle_temporal_gyrus_spiny_L3"]
    APOE_1["APOE"] -->|expressed in| middle_temporal_gyrus_asp["middle_temporal_gyrus_aspiny_L3"]
    APOE_2["APOE"] -->|expressed in| middle_temporal_gyrus_spi_3["middle_temporal_gyrus_spiny_L5"]
    APOE_4["APOE"] -->|participates in| Lipid_Metabolism___Choles["Lipid Metabolism / Cholesterol Transport"]
    APOE_5["APOE"] -->|co discussed| LAMP2["LAMP2"]
    APOE_6["APOE"] -->|co discussed| SLC17A7["SLC17A7"]
    APOE4["APOE4"] -->|co discussed| SLC17A7_7["SLC17A7"]
    APOE4_8["APOE4"] -->|co discussed| NLRP3["NLRP3"]
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style middle_temporal_gyrus_spi fill:#4fc3f7,stroke:#333,color:#000
    style APOE_1 fill:#ce93d8,stroke:#333,color:#000
    style middle_temporal_gyrus_asp fill:#4fc3f7,stroke:#333,color:#000
    style APOE_2 fill:#ce93d8,stroke:#333,color:#000
    style middle_temporal_gyrus_spi_3 fill:#4fc3f7,stroke:#333,color:#000
    style APOE_4 fill:#ce93d8,stroke:#333,color:#000
    style Lipid_Metabolism___Choles fill:#81c784,stroke:#333,color:#000
    style APOE_5 fill:#ce93d8,stroke:#333,color:#000
    style LAMP2 fill:#ce93d8,stroke:#333,color:#000
    style APOE_6 fill:#ce93d8,stroke:#333,color:#000
    style SLC17A7 fill:#ce93d8,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style SLC17A7_7 fill:#ce93d8,stroke:#333,color:#000
    style APOE4_8 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 APOE — PDB 2L7B Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

neurodegeneration | 2026-04-02 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (4)

Cell-Type Specific TREM2 Upregulation in DAM Microglia

Score: 0.76 · TREM2

GFAP-Positive Reactive Astrocyte Subtype Delineation

Score: 0.75 · GFAP

Complement C1QA Spatial Gradient in Cortical Layers

Score: 0.68 · C1QA

Excitatory Neuron Vulnerability via SLC17A7 Downregulation

Score: 0.67 · SLC17A7

→ View all analysis hypotheses

APOE Isoform Expression Across Glial Subtypes

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 35

✗ Opposing Evidence 7

Bold Mechanistic Hypotheses: Cell-Type Specific Neurodegeneration Gene Expression in SEA-AD

Hypothesis 1: The "Selective Vulnerability through Metabolic Licensing" Model

Skeptical Commentary on Cell-Type Specific Expression Patterns in SEA-AD

Cell-Type Specific Expression Patterns of Neurodegeneration Genes in SEA-AD

Price History

Clinical Trials (16) Relevance: 22%

📚 Cited Papers (78)

📅 Citation Freshness Audit

📙 Related Wiki Pages (15)

📓 Linked Notebooks (4)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (4)

🧬 Same Target Gene / Disease (27)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

Wiki Pages

KG Entities (56)

Linked Experiments (10)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (95 edges)

associated with (3)

co discussed (32)

expressed in (54)

involved in (1)

participates in (5)

Mechanism Pathway for APOE

3D Protein Structure

Source Analysis

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Community Feedback

Same Analysis (4)